Antiviral treatment using the adenosine nucleoside analogue GS‐441524 in cats with clinically diagnosed neurological feline infectious peritonitis

Bibliographic Details
Title: Antiviral treatment using the adenosine nucleoside analogue GS‐441524 in cats with clinically diagnosed neurological feline infectious peritonitis
Authors: Peter J. Dickinson, Michael Bannasch, Sara M. Thomasy, Vishal D. Murthy, Karen M. Vernau, Molly Liepnieks, Elizabeth Montgomery, Kelly E. Knickelbein, Brian Murphy, Niels C. Pedersen
Source: Journal of Veterinary Internal Medicine, Vol 34, Iss 4, Pp 1587-1593 (2020)
Publisher Information: Wiley, 2020.
Publication Year: 2020
Collection: LCC:Veterinary medicine
Subject Terms: antiviral, cat, corona virus, ophthalmology, Veterinary medicine, SF600-1100
More Details: Abstract Feline infectious peritonitis (FIP) is caused by a mutant biotype of the feline enteric coronavirus. The resulting FIP virus (FIPV) commonly causes central nervous system (CNS) and ocular pathology in cases of noneffusive disease. Over 95% of cats with FIP will succumb to disease in days to months after diagnosis despite a variety of historically used treatments. Recently developed antiviral drugs have shown promise in treatment of nonneurological FIP, but data from neurological FIP cases are limited. Four cases of naturally occurring FIP with CNS involvement were treated with the antiviral nucleoside analogue GS‐441524 (5‐10 mg/kg) for at least 12 weeks. Cats were monitored serially with physical, neurologic, and ophthalmic examinations. One cat had serial magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis (including feline coronavirus [FCoV]) titers and FCoV reverse transcriptase [RT]‐PCR) and serial ocular imaging using Fourier‐domain optical coherence tomography (FD‐OCT) and in vivo confocal microscopy (IVCM). All cats had a positive response to treatment. Three cats are alive off treatment (528, 516, and 354 days after treatment initiation) with normal physical and neurologic examinations. One cat was euthanized 216 days after treatment initiation following relapses after primary and secondary treatment. In 1 case, resolution of disease was defined based on normalization of MRI and CSF findings and resolution of cranial and caudal segment disease with ocular imaging. Treatment with GS‐441524 shows clinical efficacy and may result in clearance and long‐term resolution of neurological FIP. Dosages required for CNS disease may be higher than those used for nonneurological FIP.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1939-1676
0891-6640
04475887
Relation: https://doaj.org/toc/0891-6640; https://doaj.org/toc/1939-1676
DOI: 10.1111/jvim.15780
Access URL: https://doaj.org/article/da216336e1b044758875a91d5f2c82f1
Accession Number: edsdoj.216336e1b044758875a91d5f2c82f1
Database: Directory of Open Access Journals
More Details
ISSN:19391676
08916640
04475887
DOI:10.1111/jvim.15780
Published in:Journal of Veterinary Internal Medicine
Language:English